People · Operator
Named in public records as an officer, director or promoter · active 2018–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Io Therapeutics, Inc. | — | Biotechnology | Series A | $4.6M | $41.7M | 2023 |
| Seurat Therapeutics, Inc. | — | Biotechnology | Pre-Seed | $773K | $42.7M | 2018 |
Sharon Lew at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sharon Lew on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Martin Sanders | 2 | 2 |
| Yuan Zhang | 1 | 2 |
| Roshantha A. Chandraratna | 1 | 1 |
| Sahani Chandraratna | 1 | 1 |
| Vidyasagar Vuligonda | 1 | 1 |
| Scott A. Thacher | 1 | 1 |
| Richard Kraig | 1 | 1 |
| Martin E. Sanders | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.